Skip to main content
  • Saved

made a Post

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations

Source :

https://doi.org/10.3389/fonc.2021.630256

BackgroundOsimertinib belongs to the third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has shown positive effects in treating lung adenocarcinoma cancer. However, the subsequent resistance to Osimertinib has become a clinical challenge.Case PresentationWe present two lung adenocarcinoma cases that developed a resistance to Osimertinib.